PegBio Co., Ltd.

Quick facts

Phase 3 pipeline

• PB-201
  PB-201 is a PEGylated biologic therapeutic designed to modulate immune function or target a specific disease pathway.

Phase 1 pipeline

• glucokinase activator
• PB-119 injection
• PB 718
• PB119

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• PegBio Co., Ltd. portfolio CI brief
• PegBio Co., Ltd. pipeline updates RSS